Foghorn Therapeutics Inc. (FHTX) NASDAQ
$5.05 (0.25) (-4.72%)
Market Cap: $214.96M
As of 04/22/24 04:00 PM EDT. Market closed.
Foghorn Therapeutics Inc. (FHTX)
NASDAQ
$5.05
(0.25) (-4.72%)
Market Cap: $214.96M
As of 04/22/24 04:00 PM EDT. Market closed.
Add to Portfolio
foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
166
Address
.
PRICE CHART FOR FOGHORN THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$5.30
Days Range
$4.99 - $5.40
52 week range
$2.70 - $9.97
Volume
77,557
Avg. Volume (30 days)
81,203
Market Cap
$214.96M
Dividend Yield
-
P/E
(2.18)
Shares Outstanding
42,565,904
Open
-
Previous Close
$5.30
Days Range
$4.99 - $5.40
52 week range
$2.70 - $9.97
Volume
77,557
Avg. Volume (30 days)
81,203
Market Cap
$214.96M
Dividend Yield
-
P/E
(2.18)
Shares Outstanding
42,565,904
FINANCIAL STATEMENTS FOR FOGHORN THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR FOGHORN THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 16, 2023 | Option Exercise | $3.72 | 311,297 | 1,158,025 | 311,297 | Aug 18, 2023, 04:03 PM |
| Agresta Samuel | Chief Medical Officer | Aug 16, 2023 | Sale | $8.25 | 311,297 | 2,568,200 | 0 | Aug 18, 2023, 04:03 PM |
| GOTTSCHALK ADRIAN | Chief Executive Officer | Sep 16, 2022 | Option Exercise | $0.54 | 40,000 | 21,600 | 186,479 | Sep 19, 2022, 04:06 PM |
| GILL SIMBA | Director | Sep 12, 2022 | Option Exercise | $0.73 | 82,000 | 59,860 | 82,000 | Sep 14, 2022, 08:59 PM |
| Bellon Steven F. | Chief Scientific Officer | Aug 11, 2022 | Option Exercise | $3.72 | 1,858 | 6,912 | 121,957 | Aug 15, 2022, 06:15 PM |
| Bellon Steven F. | Chief Scientific Officer | May 25, 2022 | Option Exercise | $3.26 | 4,392 | 14,320 | 120,099 | May 27, 2022, 04:10 PM |
| DECICCO CARL | Chief Scientific Officer | Dec 09, 2021 | Option Exercise | $3.72 | 104,310 | 388,033 | 362,707 | Dec 13, 2021, 08:37 PM |
| GOTTSCHALK ADRIAN | Chief Executive Officer | Aug 20, 2021 | Option Exercise | $0.54 | 23,000 | 12,420 | 446,479 | Aug 23, 2021, 05:01 PM |
| Reine Allan | Chief Financial Officer | Aug 09, 2021 | Option Exercise | $3.72 | 26,892 | 100,038 | 53,784 | Aug 11, 2021, 04:14 PM |
| DECICCO CARL | Chief Scientific Officer | Oct 27, 2020 | Buy | $16.00 | 5,500 | 88,000 | 258,397 | Oct 29, 2020, 05:01 PM |
| Flagship Ventures Fund V General Partner LLC | 10% Owner | Oct 27, 2020 | Buy | $16.00 | 150,000 | 2,400,000 | 9,330,878 | Oct 29, 2020, 04:58 PM |
| Abu Dhabi Investment Authority | Former 10% Owner | Oct 27, 2020 | Buy | $16.00 | 150,000 | 2,400,000 | 1,231,081 | Oct 28, 2020, 06:02 AM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Agresta Samuel | Chief Medical Officer | 08/16/2023 | 1,158,025 |
| Agresta Samuel | Chief Medical Officer | 08/16/2023 | 2,568,200 |
| GOTTSCHALK ADRIAN | Chief Executive Officer | 09/16/2022 | 21,600 |
| GILL SIMBA | Director | 09/12/2022 | 59,860 |
| Bellon Steven F. | Chief Scientific Officer | 08/11/2022 | 6,912 |
| Bellon Steven F. | Chief Scientific Officer | 05/25/2022 | 14,320 |
| DECICCO CARL | Chief Scientific Officer | 12/09/2021 | 388,033 |
| GOTTSCHALK ADRIAN | Chief Executive Officer | 08/20/2021 | 12,420 |
| Reine Allan | Chief Financial Officer | 08/09/2021 | 100,038 |
| DECICCO CARL | Chief Scientific Officer | 10/27/2020 | 88,000 |
| Flagship Ventures Fund V General Partner LLC | 10% Owner | 10/27/2020 | 2,400,000 |
| Abu Dhabi Investment Authority | Former 10% Owner | 10/27/2020 | 2,400,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN FOGHORN THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 1,305,868 | 0.00021% | -6.17% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 448,350 | 0.0003% | 5.23% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 343,720 | 0.03% | No change | Growth |
| BAKER BROS. ADVISORS LP | 45,027 | 0.0033% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR FOGHORN THERAPEUTICS INC
STOCK BUYBACKS FOR FOGHORN THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.49%
1Q
06/30/2023
0.97%
2Q
03/31/2023
1.01%
3Q
12/31/2022
1.03%
4Q
09/30/2022
1.34%
5Q
06/30/2022
1.73%
6Q
03/31/2022
2.09%
7Q
12/31/2021
11.00%
8Q
09/30/2021
14.23%
9Q
06/30/2021
14.62%
10Q
03/31/2021
14.71%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR FOGHORN THERAPEUTICS INC
LOADING...